Biologiske behandlingsmuligheder ved Graves' oftalmopati

Daniel El Fassi; Claus Henrik Nielsen; Laszlo Hegedüs

Biologiske behandlingsmuligheder ved Graves' oftalmopati

Daniel El Fassi, Claus Henrik Nielsen, Laszlo Hegedüs

1 Citationer (Scopus)

Abstract

The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.

Bidragets oversatte titel	[Biological treatment options for Graves' ophthalmopathy]
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	170
Udgave nummer	24
Sider (fra-til)	2128-30
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 9 jun. 2008

Citationsformater

@article{a2cedcaf5934460f8e4e3e4f48b7085a,

title = "Biologiske behandlingsmuligheder ved Graves' oftalmopati",

abstract = "The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.",

author = "{El Fassi}, Daniel and Nielsen, {Claus Henrik} and Laszlo Heged{\"u}s",

year = "2008",

month = jun,

day = "9",

language = "Dansk",

volume = "170",

pages = "2128--30",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - Biologiske behandlingsmuligheder ved Graves' oftalmopati

AU - El Fassi, Daniel

AU - Nielsen, Claus Henrik

AU - Hegedüs, Laszlo

PY - 2008/6/9

Y1 - 2008/6/9

N2 - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.

AB - The current medical treatment options for Graves' ophthalmopathy (GO) are unsatisfactory. Recent treatment of GO patients with the B-lymphocyte depleting monoclonal antibody rituximab or with the anti-tumor necrosis factor-alpha agents etanercept and infliximab has shown promising results. We discuss the use of these and other biological agents targeting B lymphocytes, T-lymphocyte interaction with antigen-presenting cells, or cytokines in the future treatment of GO.

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 170

SP - 2128

EP - 2130

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -

Biologiske behandlingsmuligheder ved Graves' oftalmopati

Abstract

Fingeraftryk

Citationsformater